CA2936548C - The use of a benzoate containing composition in urea cycle disorders and neurodegenerative disorders - Google Patents

The use of a benzoate containing composition in urea cycle disorders and neurodegenerative disorders Download PDF

Info

Publication number
CA2936548C
CA2936548C CA2936548A CA2936548A CA2936548C CA 2936548 C CA2936548 C CA 2936548C CA 2936548 A CA2936548 A CA 2936548A CA 2936548 A CA2936548 A CA 2936548A CA 2936548 C CA2936548 C CA 2936548C
Authority
CA
Canada
Prior art keywords
mice
pharmaceutical composition
gtb
glyceryl
eae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2936548A
Other languages
English (en)
French (fr)
Other versions
CA2936548A1 (en
Inventor
Kalipada PAHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rush University Medical Center
Original Assignee
Rush University Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rush University Medical Center filed Critical Rush University Medical Center
Publication of CA2936548A1 publication Critical patent/CA2936548A1/en
Application granted granted Critical
Publication of CA2936548C publication Critical patent/CA2936548C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2936548A 2014-01-17 2015-01-16 The use of a benzoate containing composition in urea cycle disorders and neurodegenerative disorders Active CA2936548C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461928622P 2014-01-17 2014-01-17
US61/928,622 2014-01-17
PCT/US2015/011798 WO2015109215A1 (en) 2014-01-17 2015-01-16 The use of a benzoate containing composition in urea cycle disorders and neurodegenerativre disordrs

Publications (2)

Publication Number Publication Date
CA2936548A1 CA2936548A1 (en) 2015-07-23
CA2936548C true CA2936548C (en) 2022-08-30

Family

ID=53543490

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2936548A Active CA2936548C (en) 2014-01-17 2015-01-16 The use of a benzoate containing composition in urea cycle disorders and neurodegenerative disorders

Country Status (16)

Country Link
US (1) US9968582B2 (https=)
EP (1) EP3094616B1 (https=)
JP (2) JP6836905B2 (https=)
CA (1) CA2936548C (https=)
CY (1) CY1124115T1 (https=)
DK (1) DK3094616T3 (https=)
ES (1) ES2853974T3 (https=)
HR (1) HRP20210361T1 (https=)
HU (1) HUE053671T2 (https=)
LT (1) LT3094616T (https=)
PL (1) PL3094616T3 (https=)
PT (1) PT3094616T (https=)
RS (1) RS61611B1 (https=)
SI (1) SI3094616T1 (https=)
SM (1) SMT202100074T1 (https=)
WO (1) WO2015109215A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3691630A4 (en) * 2017-10-06 2021-10-27 Rush University Medical Center USE OF A COMPOSITION CONTAINING BENZOATE TO TREAT GLYCINE ENCEPHALOPATHY
TWI752282B (zh) * 2017-11-22 2022-01-11 林潔欣 苯甲酸或其鹽及衍生物用於預防或治療憂鬱症之用途
WO2020176432A1 (en) * 2019-02-25 2020-09-03 Rush University Medical Center Compositions including cinnamic acid and methods of use thereof
AU2020315331A1 (en) * 2019-07-16 2022-02-03 Rush University Medical Center Use of a benzoate containing composition to treat neurodegenerative disorders
CN116390761A (zh) * 2020-10-28 2023-07-04 拉什大学医学中心 肉桂酸苄酯组合物在治疗甘氨酸脑病和尿素循环障碍中的应用
CA3205005A1 (en) * 2020-12-16 2022-06-23 Rush University Medical Center Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders
CA3241282A1 (en) * 2021-12-16 2023-06-22 Kalipada PAHAN Benzoic acid salts for treatment of nervous system injuries and disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) * 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US20080171792A1 (en) 2006-12-28 2008-07-17 Jobdevairakkam Christopher New Use of highly concentrated formulations of 4-phenylbutyrate for treatment of certain disorders

Also Published As

Publication number Publication date
SI3094616T1 (sl) 2021-07-30
EP3094616B1 (en) 2020-12-23
PT3094616T (pt) 2021-03-03
US9968582B2 (en) 2018-05-15
JP2020037558A (ja) 2020-03-12
US20160331714A1 (en) 2016-11-17
CY1124115T1 (el) 2022-05-27
EP3094616A4 (en) 2017-08-23
SMT202100074T1 (it) 2021-05-07
PL3094616T3 (pl) 2021-05-31
DK3094616T3 (da) 2021-02-15
CA2936548A1 (en) 2015-07-23
EP3094616A1 (en) 2016-11-23
HRP20210361T1 (hr) 2021-04-16
JP2017505811A (ja) 2017-02-23
LT3094616T (lt) 2021-04-12
ES2853974T3 (es) 2021-09-20
HUE053671T2 (hu) 2021-07-28
WO2015109215A1 (en) 2015-07-23
RS61611B1 (sr) 2021-04-29
JP6836905B2 (ja) 2021-03-03

Similar Documents

Publication Publication Date Title
CA2936548C (en) The use of a benzoate containing composition in urea cycle disorders and neurodegenerative disorders
Cummings et al. Alzheimer’s disease: novel targets and investigational drugs for disease modification
Wang et al. Angelica sinensis polysaccharide attenuates CCl4-induced liver fibrosis via the IL-22/STAT3 pathway
Mondal et al. Cinnamon ameliorates experimental allergic encephalomyelitis in mice via regulatory T cells: implications for multiple sclerosis therapy
US12478598B2 (en) Compositions including cinnamic acid and methods of use thereof
RU2336870C2 (ru) Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта
Yang et al. Irbesartan suppresses lipopolysaccharide (LPS)-induced blood–brain barrier (BBB) dysfunction by inhibiting the activation of MLCK/MLC
JP2023532880A (ja) カンナビジオールによる脆弱ｘ症候群の処置
CN104519884A (zh) 轻度认知障碍的预防和/或治疗剂
Zang et al. Tenuigenin activates the IRS1/Akt/mTOR signaling by blocking PTPN1 to inhibit autophagy and improve locomotor recovery in spinal cord injury
BR112020005856A2 (pt) uso de uma composição contendo benzoato para tratar encefalopatia da glicina
CN116390761A (zh) 肉桂酸苄酯组合物在治疗甘氨酸脑病和尿素循环障碍中的应用
CN104411308B (zh) 通过给予某些合成化合物治疗阿尔茨海默病的方法
CN104173361A (zh) 宝霍苷i在制备防治阿尔茨海默病药物中的用途
US20240082184A1 (en) Improved treatment for globoid cell leukodsytrophy or krabbe disease
CN120514742A (zh) 一种预防或治疗阿尔兹海默症的益生菌剂及其应用
CN115429799A (zh) Magl抑制剂在制备预防或治疗肝炎药物中的用途
JP7796412B2 (ja) 血液脳脊髄関門保護剤
RU2805061C2 (ru) Лечение демиелинизирующих заболеваний
CN121265607A (zh) 防治脑海绵状血管畸形病变的药物及其应用
Croasdell Alzheimer’s Association International Conference 2020
Croasdell Alzheimer
HK40101082A (zh) 球形细胞脑白质营养不良症或克拉伯病的改良治疗
TW202547505A (zh) 包含ａｚｄ０７８０之醫藥組合物
CN121221648A (zh) 脆弱拟杆菌在制取治疗视神经损害的药械或食品中的应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200115

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250110

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250110